Clinical trials: Patients With Tumor
Metastatic Breast Cancer, Locally Advanced Breast Cancer
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable locally advanced breast cancer…
- Trial name
- NCT02595762
- Where
- 12 sites in Cyprus, Greece
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Nsclc
A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction
This trial was to evaluate the efficacy of intratumoral PTS injection in alleviating airway obstruction and dyspnea by improving the percentage of lumen patency of patients with central air way NSCLC tumor severe obstruction.
- Trial name
- NCT03448146
- Testing
- Para-Toluenesulfonamide
- Where
- China
- Volunteers
- 90 people
- Sponsor
- PTS International Inc.
Advanced Prostate Cancer
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT07115446
- Testing
- HS-20093, HRS-5041
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Hansoh BioMedical R&D Company
Breast Cancer
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after treatment with these agents.
- Trial name
- NCT01095003
- Testing
- Vinflunine plus Capecitabine, Capecitabine
- Where
- 110 sites in Argentina, Belarus and 19 more
- Volunteers
- 770 people
- Sponsor
- Pierre Fabre Medicament
Solid Cancers
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, dose-escalation study of MNRP1685A given by intravenous (IV) infusion as therapy for locally advanced or metastatic solid tumors.
- Trial name
- NCT00954642
- Testing
- bevacizumab, MNRP1685A, paclitaxel
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Thymic Tumors
A Study of KC1036 in Patients with Advanced Thymic Tumors
This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.
- Trial name
- NCT05683886
- Testing
- KC1036
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Advanced Cancer
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
The purpose of this study is to compare an injectable emulsion form of docetaxel to Taxotere in patients with advanced cancer.
- Trial name
- NCT00664170
- Testing
- ANX-514, docetaxel
- Where
- 13 sites in United States, Argentina and 1 more
- Volunteers
- 39 people
- Sponsor
- Mast Therapeutics, Inc.
Pancreatic Cancer
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
This study will compare the efficacy and safety of escalating versus standard doses to rash of Tarceva, in combination with gemcitabine, in patients with metastatic pancreatic cancer.
- Trial name
- NCT00652366
- Testing
- Erlotinib, escalating dose, Erlotinib, standard dose, Gemcitabine
- Where
- 89 sites in Argentina, Australia and 21 more
- Volunteers
- 467 people
- Sponsor
- Hoffmann-La Roche
Radiodermatitis
Topical Use of Difinsa53™ to Prevent Radiation Dermatitis
Phase II trial of the silibin containing cream, Difinsa53 to determine efficacy in delaying, ameliorating, or preventing radiation dermatitis in patients with breast cancer undergoing whole breast radiation.
- Trial name
- NCT02534129
- Testing
- Difinsa53, Aquaphor
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- ProTechSure Scientific, Inc.
Gastric Cancer, Gastroesophageal Junction Cancer
GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)
This is a prospective, non-interventional, observational, multicentre study evaluating the real-world effectiveness and safety of AstraZeneca-developed and approved medicines used to treat gastric and/or oesophageal cancers in…
- Trial name
- GRACE-DE (NCT07882212)
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Recurrent Head and Neck Squamous Cell Carcinoma
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases.
- Trial name
- ECLIPSE (NCT06699212)
- Testing
- ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin
- Where
- 22 sites in United States, Japan and 1 more
- Volunteers
- 412 people
- Sponsor
- Rakuten Medical, Inc.
Medullary Thyroid Carcinoma
A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
This is a single-arm, open-label, multicenter study designed to evaluate the preliminary antineoplastic activity, safety and tolerability of HA121-28 tablets administered orally in patients with medullary thyroid cancer (MTC).
- Trial name
- NCT04787328
- Testing
- HA121-28 tablets
- Where
- 13 sites in China
- Volunteers
- 30 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Non-Small Cell Lung Cancer
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
This study is an open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with…
- Trial name
- NCT05240131
- Testing
- GB1211, Atezolizumab
- Where
- 5 sites in France, Poland and 1 more
- Volunteers
- 88 people
- Sponsor
- Galecto Biotech AB
Advanced Solid Tumors
GenSci139 in Patients With Advanced Solid Tumors
This is a phase I, two-part, multicenter, first-in-human study. The Part 1 study will assess the safety, tolerability, preliminary anti-tumor activities, PK profile, immunogenicity and biomarker of GenSci139 in participants with…
- Trial name
- NCT07230977
- Testing
- GenSci139
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Malignant Pleural Effusions, NSCLC Stage IV
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
- Trial name
- NCT05543330
- Testing
- M701 pleural infusion, Pleural drainage, Cisplatin pleural infusion
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Colorectal Cancer (Locally Advanced or Metastatic)
A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
SOT109 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called CDH17, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B.
- Trial name
- NCT07693751
- Testing
- SOT109
- Where
- 3 sites in United States, Moldova
- Volunteers
- 100 people
- Sponsor
- SOTIO Biotech a.s.
HER-2 Positive Breast Cancer, Metastatic Breast Cancer
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat when given in combination with trastuzumab and paclitaxel.
- Trial name
- NCT00788931
- Testing
- IV LBH589, Oral LBH589, trastuzumab
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma (Skin)
Nitrocamptothecin in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Trial name
- NCT00005875
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Diffuse, Large B-Cell, Lymphoma
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
The purpose of this study is to comparing the Efficacy and Safety between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients.
- Trial name
- NCT02867566
- Testing
- IBI301 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Solid Tumor
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Study 516-010 is an open-label Phase 1, drug-drug interaction and QTc study evaluating the effect of sitravatinib on probe substrates for CYP450 enzymes and BCRP and P-gp transporters.
- Trial name
- NCT04887194
- Testing
- Sitravatinib, Warfarin, Dextromethorphan
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.